Irinotesin

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotesin, is a topoisomerase I inhibitor presented as a sterile powder for reconstitution for intravenous use. It is employed in the treatment of colorectal cancer in adult patients. It is indicated for patients with metastatic or locally advanced disease and is administered under the supervision of qualified oncology specialists.

GNH USA supplies Irinotesin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to EU GMP standards and provides reliable cold‑chain logistics where required.

Irinotesin (irinotecan) is used in the management of colorectal cancer, a malignancy of the large intestine. Colorectal cancer: improves survival when combined with fluoropyrimidine‑based chemotherapy. Metastatic colorectal cancer: reduces tumor burden in patients with advanced disease. Adjuvant colorectal cancer: used after surgical resection to lower recurrence risk.

Irinotecan therapy is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Diarrhea, which may be severe - Neutropenia (low white blood cell count) - Fatigue and weakness - Alopecia (hair loss) - Anemia

Serious or Rare Side Effects: - Febrile neutropenia (infection with fever) - Severe colitis or intestinal perforation - Allergic reactions including anaphylaxis - Hepatotoxicity (liver enzyme elevation) - Pulmonary toxicity such as interstitial pneumonitis - Hemorrhagic events

Prior to and during treatment with Irinotesin, several safety measures should be observed. Monitor blood counts: perform regular CBC to detect neutropenia. Assess liver function: evaluate hepatic enzymes before and during therapy. Hydration: ensure adequate fluid intake to mitigate diarrhea. Avoid concurrent myelosuppressive agents: reduce risk of severe bone marrow suppression. Pregnancy and lactation: contraindicated unless benefits outweigh risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan may interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Concurrent use with other topoisomerase I inhibitors: additive toxicity. - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce irinotecan exposure. - Live vaccines: increased risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may increase drug exposure. - Anticoagulants such as warfarin: monitor INR for bleeding risk. - Nephrotoxic agents (e.g., cisplatin): may enhance renal toxicity.